Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJH 295 is an irreversible Nek2 inhibitor (IC50=770 nM). Inhibits Nek2 via alkylation of residue Cys22. Displays 5-fold selectivity for Nek2 over Cdk1. Exhibits no significant effect on Aurora B or Plk1 kinases, bipolar spindle assembly or spindle assembly checkpoint. Cell permeable.
分子量 | 320.35 |
公式 | C18H16N4O2 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1311143-71-1 |
PubChem ID | 53262909 |
InChI Key | ORKOHXAJFGRZCL-LCYFTJDESA-N |
Smiles | O=C2NC1=CC=C(NC(C#C)=O)C=C1/C2=C/C3=C(C)N=C(CC)N3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 32.03 | 100 |
以下数据基于产品分子量 320.35。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.12 mL | 15.61 mL | 31.22 mL |
5 mM | 0.62 mL | 3.12 mL | 6.24 mL |
10 mM | 0.31 mL | 1.56 mL | 3.12 mL |
50 mM | 0.06 mL | 0.31 mL | 0.62 mL |
参考文献是支持产品生物活性的出版物。
Henise et al (2011) Irreversible Nek2 kinase inhibitors with cellular activity. J.Med.Chem. 54 4133 PMID: 21627121
If you know of a relevant reference for JH 295, please let us know.
关键词: JH 295, JH 295 supplier, JH295, Nek2, inhibitor, inhibits, irreversible, alkylation, Kinase, 4322, Tocris Bioscience
目前没有该产品的评论。 Be the first to review JH 295 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.